Nuveen Asset Management, LLC Immuneering Corp Transaction History

Nuveen Asset Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$4.84 - $8.44 $16,959 - $29,573	3,504 Added 8.64%	44,049 $323,000
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $263,137 - $541,681	40,545 New	40,545 $411,000
Q2 2022 Aug 15, 2022	SELL	$3.89 - $7.81 $105,212 - $211,237	-27,047 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.47 - $16.99 $98,906 - $259,726	15,287 Added 129.99%	27,047 $196,000
Q3 2021 Nov 12, 2021	BUY	$17.0 - $32.84 $199,920 - $386,198	11,760 New	11,760 $312,000

4.64M

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $55.4M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.